Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum

PURPOSE: The purpose of this study was to evaluate the anti-tumor activity and safety of anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with gemcitabine plus platinum (GP) as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). PATIENTS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chen, Zhang, Xuanye, Zhou, Yixin, Fu, Sha, Lin, Zuan, Hong, Shaodong, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585779/
https://www.ncbi.nlm.nih.gov/pubmed/33116890
http://dx.doi.org/10.2147/CMAR.S275947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585779/
https://www.ncbi.nlm.nih.gov/pubmed/33116890
http://dx.doi.org/10.2147/CMAR.S275947

Ejemplares similares